Form 8-K - Current report:
SEC Accession No. 0001493152-24-038339
Filing Date
2024-09-26
Accepted
2024-09-26 17:00:10
Documents
13
Period of Report
2024-09-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39294
  Complete submission text file 0001493152-24-038339.txt   216334

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE prph-20240920.xsd EX-101.SCH 3027
3 XBRL LABEL FILE prph-20240920_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE prph-20240920_pre.xml EX-101.PRE 24173
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3687
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 241329658
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)